MHRA announces corporate plan for 2023-2026
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has published its corporate plan for the next three years, featuring a focus on patient access to innovation.
#patients
Tag
New drug costs threaten NHS financial stability, says report
The new report, ‘Promoting population health through pharmaceutical policy: The role of the UK Voluntary Scheme’, produced by researchers at the London School of Economics, London School of Hygiene & Tropical Medicine (LSHTM) and University of York, investigates the costs of prescription medicines to the NHS in England.
US FDA issues draft guidance on decentralised clinical trials
Decentralised clinical trials (DCTs) are being used increasingly in the pharma industry for clinical research and the US Food and Drug Administration (FDA) has published draft guidance for those carrying out trials at non-traditional investigation sites.
Will ABPI’s ambitious VPAG plans succeed VPAS?
Discussions are beginning on the next iteration of the UK’s voluntary scheme for branded medicines, pricing and access (VPAS) and the Association of the British Pharmaceutical Industry (ABPI) has set out its stall to government. It has published a four-point proposal for a Voluntary Scheme for Pricing, Access and Growth (VPAG), designed to reignite competitiveness and boost innovation in the life sciences sector, thereby improving health outcomes and the wider economy.